Nephron progenitor cell differentiation is negatively regulated by the extracellular matrix protein decorin, according to findings in mice just published by researchers at the Maine Medical Centre Research Institute, Scarborough, USA.

Transgenic mice with targeted deletion of forkhead box protein D1 (Foxd1−/− mice) show accumulation of undifferentiated nephron progenitor cells, indicating a role for this transcription factor (which is expressed during kidney development and regulates many extracellular matrix proteins) in nephrogenesis. Intriguingly, forkhead box protein D1 is expressed not in nephron progenitor cells, but in adjacent interstitial cells, suggesting that the interstitial cells secrete factors that regulate nephron progenitor cell differentiation. To identify these factors, the researchers compared the transcriptional profiles of kidney cells from Foxd1−/− mice with those of their wild-type littermates.

The most prominent differentially expressed gene was Dcn, which encodes decorin, a potent antagonist of TGF-β signalling implicated in renal fibrosis. Overexpression of forkhead box protein D1 repressed expression of Dcn; conversely, decorin accumulated around renal progenitor cells in Foxd1−/− mice. Further, decorin antagonized the response of nephron progenitor cells to BMP-7, a protein previously demonstrated to be essential for nephron progenitor cell differentiation. When the investigators genetically inactivated Dcn in Foxd1−/− mice, the failure of progenitor cell differentiation was partially ameliorated in the resulting dual-knockout mice. Overall, the findings suggest that decorin promotes retention of nephron progenitor cells in an undifferentiated state through inhibition of BMP-7 signalling.

The researchers also found that forkhead box protein D1 expression maintains interstitial cells in an undifferentiated progenitor-like cell state. “Cells of the Foxd1 lineage expand in kidney fibrosis and understanding mechanisms regulating the differentiation state of this lineage could identify pathways of clinical importance in chronic kidney disease,” states lead investigator Leif Oxburgh.